hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06274580, orgStudyIdInfo id: 5916, briefTitle: Endovascular vs Conservative Treatment in Patients With Chronic Subdural Hematomas and Mild Symptoms, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-03-01, completionDateStruct date: 2026-03-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Ospedale Policlinico San Martino, class: OTHER, descriptionModule briefSummary: Embotrial-1 is an Italian multicenter prospective randomized clinical trial with open-label treatment and blinded outcome assessment (PROBE) to assess the superiority of MMA embolization compared to conservative treatment. The intervention group is MMA embolization and comparator control group is the conservative management with best medical treatment. Patients are randomized 1:1., conditionsModule conditions: Subdural Hematoma, Chronic, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: embolization of the middle meningeal artery, outcomesModule primaryOutcomes measure: Rate of incomplete hematoma resolution or surgical rescue, secondaryOutcomes measure: treatment complication, secondaryOutcomes measure: treatment successful, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06274567, orgStudyIdInfo id: 2024P000348, briefTitle: Intermittent Theta Burst Stimulation (iTBS) for Emotion Regulation in Bipolar Disorder, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2028-08-31, completionDateStruct date: 2029-03-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Massachusetts General Hospital, class: OTHER, collaborators name: University of Pennsylvania, descriptionModule briefSummary: The objective of this study protocol is to test whether intermittent theta-burst transcranial magnetic stimulation (iTBS-TMS) to the inferior parietal lobule (IPL) can strengthen functional connectivity with a key region in emotion regulation (ER) neurocircuitry (anterior insula, AI) and improve performance on ER-related tasks in patients with bipolar disorder. Individual IPL sites for stimulation will be identified through baseline, pre-TMS functional magnetic resonance imaging (fMRI) scans. Patient-specific IPL subregions showing positive functional connectivity with the anterior insula and falling within the patient-specific frontoparietal control network will be used as individualized target sites for TMS stimulation. Patients will be randomized to receive 24 sessions of active versus sham iTBS to patient-specific IPL targets (6 sessions/day, 4 days, 43,200 pulses total). Post-iTBS resting-state and task-based fMRI scans will be acquired 3 days after the final day of iTBS administration (Day 4) following identical procedures as baseline. Effects of iTBS-TMS on ER will be evaluated by comparing pre-TMS versus post-TMS functional connectivity and behavior during performance on ER tasks., conditionsModule conditions: Bipolar Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized allocation, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: We will use an active/placebo TMS coil. TMS operator and participant will be blinded to active versus sham. Investigator will be blinded to participant condition assignment., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 136, type: ESTIMATED, armsInterventionsModule interventions name: Transcranial Magnetic Stimulation (TMS), interventions name: Sham (placebo) TMS, outcomesModule primaryOutcomes measure: Correlated functional magnetic resonance imaging (fMRI) time series (functional connectivity), secondaryOutcomes measure: Affective Multisource Interference Task, secondaryOutcomes measure: Balloon Analogue Risk Task, eligibilityModule sex: ALL, minimumAge: 24 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Martinos Center for Biomedical Imaging, city: Charlestown, state: Massachusetts, zip: 02129, country: United States, geoPoint lat: 42.37787, lon: -71.062, hasResults: False
protocolSection identificationModule nctId: NCT06274554, orgStudyIdInfo id: 23-11026746, briefTitle: Testing the Role for Anti-fungal Therapy in Improving the Response to Medicine for Crohn's Disease, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2028-12, completionDateStruct date: 2029-12, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Weill Medical College of Cornell University, class: OTHER, collaborators name: The Leona M. and Harry B. Helmsley Charitable Trust, descriptionModule briefSummary: The goal of this clinical trial is to learn about the effects of fluconazole in patients who plan to or are undergoing standard of care treatment with an IL-23 therapy for their Crohn's disease.The main question it aims to assess is will patient response to IL-23 therapies improve when simultaneously treated with fluconazole., conditionsModule conditions: Crohn's Disease, conditions: Inflammatory Bowel Diseases, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, maskingDescription: Double-blinded study, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 120, type: ESTIMATED, armsInterventionsModule interventions name: Fluconazole, interventions name: Placebo, interventions name: IL-23 Therapy, outcomesModule primaryOutcomes measure: Proportion of subjects achieving clinical response, secondaryOutcomes measure: Proportion of subjects achieving clinical remission, secondaryOutcomes measure: Proportion of patients achieving endoscopic response or remission, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Weill Cornell Medicine, city: New York, state: New York, zip: 10065, country: United States, contacts name: Grace Xiang, BS, role: CONTACT, phone: 646-697-0985, email: grx4001@med.cornell.edu, contacts name: Randy Longman, MD, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Dana Lukin, MD, PhD, role: SUB_INVESTIGATOR, contacts name: Ellen Scherl, MD, role: SUB_INVESTIGATOR, contacts name: Iliyan Iliev, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.71427, lon: -74.00597, hasResults: False
protocolSection identificationModule nctId: NCT06274502, orgStudyIdInfo id: deep learning, briefTitle: Automated Detection and Diagnosis of Pathological DRGs in PHN Patients Using Deep Learning and Magnetic Resonance, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-10-01, primaryCompletionDateStruct date: 2024-01-31, completionDateStruct date: 2024-01-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Huazhong University of Science and Technology, class: OTHER, descriptionModule briefSummary: Here, this study aimed to develop an automated system for detecting and diagnosing lesion DRGs in PHN patients based on deep learning. This study retrospectively analyzed the DRG images of all patients with postherpetic neuralgia who underwent magnetic resonance neuroimaging examinations in our radiology department from January 2021 to February 2022. After image post-processing, the You Only Look Once (YOLO) version 8 was selected as the target algorithm model. Model performance was evaluated using metrics such as precision, recall, Average Precision, mean average precision and F1 score., conditionsModule conditions: Deep Learning, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 41, type: ACTUAL, armsInterventionsModule interventions name: YOLOv8, outcomesModule primaryOutcomes measure: Develop an automated system for detecting and diagnosing lesion DRGs in PHN patients based on deep learning, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 85 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, city: Wuhan, state: Hubei, zip: 430030, country: China, geoPoint lat: 30.58333, lon: 114.26667, locations facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, city: Wuhan, country: China, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06274476, orgStudyIdInfo id: 2020/9/9, briefTitle: Prosthetic Rehabilitation of Thin Wiry Ridge by Ridge Splitting and Simultaneous Implants Placement, acronym: implant, statusModule overallStatus: COMPLETED, startDateStruct date: 2018-09-09, primaryCompletionDateStruct date: 2019-12-09, completionDateStruct date: 2020-01-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: evaluates the success of prosthetic rehabilitation of thin wiry ridge and implants placed simultaneously in splitted ridge both clinically and radiographically., conditionsModule conditions: Atrophic Maxillary Ridge and Mandibular Ridge, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: maxillary and mandibular atrophic ridge, primaryPurpose: OTHER, maskingInfo masking: DOUBLE, maskingDescription: double, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 21, type: ACTUAL, armsInterventionsModule interventions name: implant placement, outcomesModule primaryOutcomes measure: implant success, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mohamed yahia Sharaf, city: Zagazig, state: Sharkia, zip: 44715, country: Egypt, geoPoint lat: 30.58768, lon: 31.502, hasResults: False
protocolSection identificationModule nctId: NCT06274463, orgStudyIdInfo id: 2023-11-035, briefTitle: A Personalized Trunk Stability Exercise Program Study With Brain Disease Patients, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-02-21, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Bundang CHA Hospital, class: OTHER, descriptionModule briefSummary: To investigate the effect on improving trunk stability and satisfaction with the program when a customized trunk stabilization exercise program personalized to the subject's functional level is applied to patients with brain disease., conditionsModule conditions: Brain Diseases, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Exercise therapy including a trunk stabilization exercise program, outcomesModule primaryOutcomes measure: Trunk Impairment Scale, primaryOutcomes measure: Berg Balance Scale, secondaryOutcomes measure: Joint angle, secondaryOutcomes measure: Joint moment, secondaryOutcomes measure: Joint power, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06274450, orgStudyIdInfo id: C2202112, briefTitle: A Clinical Study on the Improvement of Skin and Living Conditions After Drinking Rosa Roxburghii and Pomegranate Drinks, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-07-06, primaryCompletionDateStruct date: 2022-09-02, completionDateStruct date: 2022-09-02, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Botanee Group Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The main objective of the study is to observe changes in the subjects' skin condition and life status after 8 weeks of drinking rosa roxburghii and pomegranate drinks.This is a single-center, randomized, single-blind, controlled, 8-week (56-day) clinical study conducted in Chinese healthy women aged 25-45 years old who were offered a rosa roxburghii and pomegranate drink., conditionsModule conditions: Skin Laxity, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 70, type: ACTUAL, armsInterventionsModule interventions name: skin care product, interventions name: Drinks with active ingredients Rosa Roxburghii and Pomegranate, outcomesModule primaryOutcomes measure: Changes in the skin hydration, primaryOutcomes measure: Changes in the skin glossiness, primaryOutcomes measure: Changes in the skin firmness, primaryOutcomes measure: Changes in the skin elasticity, primaryOutcomes measure: Changes in the individual type angle, primaryOutcomes measure: Changes in the melanin content, primaryOutcomes measure: Changes in the proportion of crow's feet area, primaryOutcomes measure: Changes in the proportion of fine lines under the eye, primaryOutcomes measure: Changes in the CIE RGB of skin tone, primaryOutcomes measure: Changes in the grade of Pigmentation, primaryOutcomes measure: Skin condition Assessment after 4-week application, primaryOutcomes measure: Skin condition Assessment after 8-week application, secondaryOutcomes measure: Changes in the satisfaction with the quality of life, eligibilityModule sex: FEMALE, minimumAge: 25 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Shanghai China-norm Quality Technical Service Co ，Ltd, city: Shanghai, state: Shanghai, zip: 200072, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06274424, orgStudyIdInfo id: HUS/211/2016 and HUS/2699/2018, briefTitle: Hair Cortisol and Symptoms in Children With Psychopathology During CBT, statusModule overallStatus: COMPLETED, startDateStruct date: 2016-07-01, primaryCompletionDateStruct date: 2019-10-01, completionDateStruct date: 2019-10-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-29, sponsorCollaboratorsModule leadSponsor name: Helsinki University Central Hospital, class: OTHER, descriptionModule briefSummary: This study aims to examine the relationship between hair cortisol concentration and behavior and sleep disturbance symptoms in children with psychiatric disorders. It also investigates potential changes in hair cortisol and symptomatology after group-based cognitive behavior therapy. Furthermore, the study explores the effects of any alterations in hair cortisol concentration levels on potential behavior and sleep disturbance symptom change over the course of the study., conditionsModule conditions: Child Behavior Problem, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 100, type: ACTUAL, armsInterventionsModule interventions name: The Friends Program, outcomesModule primaryOutcomes measure: Hair Cortisol Concentration, primaryOutcomes measure: Parent- and teacher rated internalizing and externalizing symptoms, primaryOutcomes measure: Child-rated internalizing symptoms, primaryOutcomes measure: Parent-rated sleep disturbance symptoms, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 13 Years, stdAges: CHILD, hasResults: False
protocolSection identificationModule nctId: NCT06274411, orgStudyIdInfo id: KS2024014, briefTitle: Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention, acronym: ESCORT, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2025-12-31, completionDateStruct date: 2026-03-01, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Beijing Anzhen Hospital, class: OTHER, descriptionModule briefSummary: The goal of this multicenter, randomized trial is to compare standby cannulated ECMO versus prophylactic ECMO in patients undergoing high-risk percutaneous coronary intervention (PCI). The main question it aims to answer is :• If standby cannulated ECMO as compared with prophylactic ECMO will improve the outcomes in patients undergoing high-risk PCI, conditionsModule conditions: ECMO, conditions: High-risk PCI, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 176, type: ESTIMATED, armsInterventionsModule interventions name: Standby cannulated ECMO, interventions name: Prophylactic ECMO, outcomesModule primaryOutcomes measure: Composite rate of 8 major adverse events, secondaryOutcomes measure: Platelet drop, secondaryOutcomes measure: Duration of ECMO support, secondaryOutcomes measure: Length of hospital stay, secondaryOutcomes measure: Hemoglobin drop, secondaryOutcomes measure: Serum interleukin-6 concentration, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Anzhen Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100029, country: China, contacts name: Liangshan Wang, MD, role: CONTACT, phone: 86-13811363372, email: wangliangshanbam@sina.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06274398, orgStudyIdInfo id: RITE Study, briefTitle: Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study, acronym: RITE PrEP, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-16, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Eastern Virginia Medical School, class: OTHER, collaborators name: CONRAD, collaborators name: Emory University, collaborators name: Centers for Disease Control and Prevention, descriptionModule briefSummary: This is a double-blind, placebo-controlled, randomized two-phase study to evaluate the safety and pharmacokinetics (PK) of two TAF/EVG inserts administered rectally for 3 consecutive days, then every other day for 14 days., conditionsModule conditions: Safety Issues, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Randomized, Placebo-controlled, Double-blind, primaryPurpose: OTHER, maskingInfo masking: QUADRUPLE, maskingDescription: Double-blind, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: TAF/EVG rectal insert, interventions name: Matching placebo rectal insert, outcomesModule primaryOutcomes measure: Frequency and intensity of Adverse Events, primaryOutcomes measure: Pharmacokinetics (PK) (maximum concentration (Cmax)) in blood, primaryOutcomes measure: PK (Cmax) in rectal secretions, primaryOutcomes measure: PK (Cmax) in rectal mucosal tissue, secondaryOutcomes measure: PK (Cmax) in cervicovaginal secretions, secondaryOutcomes measure: PK (Cmax) in cerviocovaginal mucosal tissues, secondaryOutcomes measure: Cytokine Profiles, secondaryOutcomes measure: Microbiome Profiles, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 59 Years, stdAges: ADULT, contactsLocationsModule locations facility: Emory Clinic, status: RECRUITING, city: Atlanta, state: Georgia, zip: 30322, country: United States, contacts name: Cassie Grimsley Ackerley, MD, MSc, role: CONTACT, email: cassie.marie.grimsley.ackerley@emory.edu, geoPoint lat: 33.749, lon: -84.38798, hasResults: False
protocolSection identificationModule nctId: NCT06274385, orgStudyIdInfo id: 2311010178, briefTitle: The Effects of an Acute Dose of a Betalain-rich Concentrate on Repeated-sprint Cycling Performance and Recovery., acronym: BET_RSE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02, primaryCompletionDateStruct date: 2024-06, completionDateStruct date: 2024-06, studyFirstPostDateStruct date: 2024-02-23, lastUpdatePostDateStruct date: 2024-02-23, sponsorCollaboratorsModule leadSponsor name: Drexel University, class: OTHER, descriptionModule briefSummary: Betalains have well-known antioxidant and anti-inflammatory properties. Recent investigations examining the effects of a betalain-rich concentrate (BRC) on exercise and recovery performance show promise of BRC as an ergogenic aid. To date, no study has examined the effects of a single dose of a BRC on supramaximal performance and recovery. Therefore, the purpose of this study is to examine the effects of an acute dose of BRC on repeated-sprint cycling performance and recovery., conditionsModule conditions: Nutraceuticals, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 10, type: ESTIMATED, armsInterventionsModule interventions name: Betalain-rich concentrate (AltRed), interventions name: Placebo, outcomesModule primaryOutcomes measure: Repeated Sprint Performance, secondaryOutcomes measure: Neuromuscular Fatigue, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 40 Years, stdAges: ADULT, contactsLocationsModule locations facility: Drexel University - Health Sciences Building, status: RECRUITING, city: Philadelphia, state: Pennsylvania, zip: 19102, country: United States, contacts name: Arun Ramakrishnan, PhD, role: CONTACT, phone: 215-553-7018, email: ar88@drexel.edu, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False